Drug
Recaticimab clinical trials
Also written SHR-1209.
- studies test it
- 17
- open now
- 10
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the recaticimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
17 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 4
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 10
Jiangsu HengRui Medicine Co., Ltd. (7) · Peking Union Medical College Hospital (3) · Hunan Cancer Hospital (1) · Peking University Cancer Hospital & Institute (1) · Second Affiliated Hospital of Nanchang University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · Shanghai East Hospital (1)
Often tested with
Tested in the same studies.
Adebrelimab (3) · SHR-1701 (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Carboplatin (1)
Studies
Open first, then newest update. How each study uses recaticimab is read from its arms, and is right about nine times in ten.
Testing it · 17
- Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter TrialNot yet recruitingPhase 4Peking Union Medical College HospitalNCT07605130Written as Recaticimab
- Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery OcclusionRecruitingPhase 3Shanghai East HospitalNCT07002476Written as Recaticimab (intensive)
- PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic StrokeNot yet recruitingPhase 4Peking Union Medical College HospitalNCT07466251Written as Recaticimab plus standard therapy
- Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedNot yet recruitingPhase 4Hunan Cancer HospitalNCT07674368Written as Recaticimab
- PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial AtherosclerosisRecruitingPhase 4Peking Union Medical College HospitalNCT06902740Written as Recaticimab and Statin
- Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLCNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07567326Written as Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy
- Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative PeriodNot yet recruitingPhase 4Second Affiliated Hospital of Nanchang UniversityNCT07290699Written as Recaticimab
- PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic StenosisNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07119918Written as Recaticimab
- A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07062328Written as Recaticimab and Adebrelimab
- Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLCRecruitingPhase 2Beijing Chest Hospital, Capital Medical UniversityNCT06467617Written as Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab
- Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy VolunteersCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06837077Written as SHR-1209 single-site subcutaneous injection
- Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ StageCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04849000Written as SHR-1209
- SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical ResearchCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04844125Written as SHR-1209
- Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy VolunteersCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05370950Written as SHR-1209
- The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With HyperlipidemiaCompletedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT03944109Written as SHR-1209
- The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03634436Written as SHR-1209
- A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial HypercholesterolemiaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04455581Written as SHR-1209
Codes
What other systems call recaticimab · ClinicalTrials.gg INT014377
- UNII (FDA) 20IE6M67UXRECATICIMABOne source FDA
- NCI Thesaurus C175849RecaticimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 20IE6M67UX | RECATICIMAB | One source FDA |
| NCI Thesaurus | C175849 | Recaticimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.